中华实验外科杂志
中華實驗外科雜誌
중화실험외과잡지
CHINESE JOURNAL OF EXPERIMENTAL SURGERY
2013年
9期
1918-1920
,共3页
袁小旭%郑伏甫%卞军%叶云林%赖德辉%戴宇平
袁小旭%鄭伏甫%卞軍%葉雲林%賴德輝%戴宇平
원소욱%정복보%변군%협운림%뢰덕휘%대우평
肾癌%启动子甲基化%TMEFF2
腎癌%啟動子甲基化%TMEFF2
신암%계동자갑기화%TMEFF2
Renal carcinoma%Promoter methylation%Transmembrane protein with epidermal growth factor-like and two follistatin-like domains 2
目的 观察肾癌石蜡标本中TMEFF2基因启动子甲基化状态,及其与各项临床指标的关系.方法 采用甲基化特异性聚合酶链反应(MSP)方法,探讨42例肾透明细胞癌石蜡标本中TMEFF2启动子甲基化与临床指标如肿瘤分期、预后等的关系.结果 42例肾透明细胞癌石蜡标本中,TMEFF2启动子甲基化状态(17例为非甲基化,13例为部分甲基化,12例呈甲基化)；各组之间T分期(非甲基化组:T1期14例、T2期2例、T3期1例、T4期0例；部分甲基化组:T1期4例、T2期4例、T3期3例、T4期2例；甲基化组:T1期2例、T2期10例、T3期例、T4期0例；)、AJCC肾癌分期(非甲基化组:Ⅰ期12例、Ⅱ期1例、Ⅲ期0例、Ⅳ期4例；部分甲基化组:Ⅰ期2例、Ⅱ期4例、Ⅲ期2例、Ⅳ期5例；甲基化组:Ⅰ期1例、Ⅱ期10例、Ⅲ期l例、Ⅳ期0例)、总胆汁酸[TBA,非甲基化组(7.43±4.59) μmol/L,部分甲基化组(4.44±1.75) μmol/L,甲基化组(3.97±3.57) μmol/L]、肌酐[CRE,非甲基化组(91.7± 24.8)μmol/L,部分甲基化组(109.0±22.2)μmol./L,甲基化组(82.7±19.1)μmol/L]、胆固醇[CHO,非甲基化组(4.88±0.95) mmol/L,部分甲基化组(4.78±1.14)mmol/L,甲基化组(3.97 ±0.69) mmol/L]、肿瘤直径[非甲基化组(5.44±1.96) cm,部分甲基化组(7.15 ±3.10) cm,甲基化组(8.22±2.60) cm]差异有统计学意义(P＜0.05).结论 TMEFF2可能参与了肾癌的发生、发展过程.
目的 觀察腎癌石蠟標本中TMEFF2基因啟動子甲基化狀態,及其與各項臨床指標的關繫.方法 採用甲基化特異性聚閤酶鏈反應(MSP)方法,探討42例腎透明細胞癌石蠟標本中TMEFF2啟動子甲基化與臨床指標如腫瘤分期、預後等的關繫.結果 42例腎透明細胞癌石蠟標本中,TMEFF2啟動子甲基化狀態(17例為非甲基化,13例為部分甲基化,12例呈甲基化)；各組之間T分期(非甲基化組:T1期14例、T2期2例、T3期1例、T4期0例；部分甲基化組:T1期4例、T2期4例、T3期3例、T4期2例；甲基化組:T1期2例、T2期10例、T3期例、T4期0例；)、AJCC腎癌分期(非甲基化組:Ⅰ期12例、Ⅱ期1例、Ⅲ期0例、Ⅳ期4例；部分甲基化組:Ⅰ期2例、Ⅱ期4例、Ⅲ期2例、Ⅳ期5例；甲基化組:Ⅰ期1例、Ⅱ期10例、Ⅲ期l例、Ⅳ期0例)、總膽汁痠[TBA,非甲基化組(7.43±4.59) μmol/L,部分甲基化組(4.44±1.75) μmol/L,甲基化組(3.97±3.57) μmol/L]、肌酐[CRE,非甲基化組(91.7± 24.8)μmol/L,部分甲基化組(109.0±22.2)μmol./L,甲基化組(82.7±19.1)μmol/L]、膽固醇[CHO,非甲基化組(4.88±0.95) mmol/L,部分甲基化組(4.78±1.14)mmol/L,甲基化組(3.97 ±0.69) mmol/L]、腫瘤直徑[非甲基化組(5.44±1.96) cm,部分甲基化組(7.15 ±3.10) cm,甲基化組(8.22±2.60) cm]差異有統計學意義(P＜0.05).結論 TMEFF2可能參與瞭腎癌的髮生、髮展過程.
목적 관찰신암석사표본중TMEFF2기인계동자갑기화상태,급기여각항림상지표적관계.방법 채용갑기화특이성취합매련반응(MSP)방법,탐토42례신투명세포암석사표본중TMEFF2계동자갑기화여림상지표여종류분기、예후등적관계.결과 42례신투명세포암석사표본중,TMEFF2계동자갑기화상태(17례위비갑기화,13례위부분갑기화,12례정갑기화)；각조지간T분기(비갑기화조:T1기14례、T2기2례、T3기1례、T4기0례；부분갑기화조:T1기4례、T2기4례、T3기3례、T4기2례；갑기화조:T1기2례、T2기10례、T3기례、T4기0례；)、AJCC신암분기(비갑기화조:Ⅰ기12례、Ⅱ기1례、Ⅲ기0례、Ⅳ기4례；부분갑기화조:Ⅰ기2례、Ⅱ기4례、Ⅲ기2례、Ⅳ기5례；갑기화조:Ⅰ기1례、Ⅱ기10례、Ⅲ기l례、Ⅳ기0례)、총담즙산[TBA,비갑기화조(7.43±4.59) μmol/L,부분갑기화조(4.44±1.75) μmol/L,갑기화조(3.97±3.57) μmol/L]、기항[CRE,비갑기화조(91.7± 24.8)μmol/L,부분갑기화조(109.0±22.2)μmol./L,갑기화조(82.7±19.1)μmol/L]、담고순[CHO,비갑기화조(4.88±0.95) mmol/L,부분갑기화조(4.78±1.14)mmol/L,갑기화조(3.97 ±0.69) mmol/L]、종류직경[비갑기화조(5.44±1.96) cm,부분갑기화조(7.15 ±3.10) cm,갑기화조(8.22±2.60) cm]차이유통계학의의(P＜0.05).결론 TMEFF2가능삼여료신암적발생、발전과정.
Objective To investigate the methylation status of transmembrane protein with epidermal growth factor (EGF)-like and two follistatin-like domains 2 (TMEFF2) in renal carcinoma cell line 786-0 and renal cell carcinoma specimen.Methods By MSP we investigated the relationship between methylation status of TMEFF2 in 42 paraffin-embedded clear cell renal cell carcinoma (RCC) specimens and their clinical features such as tumor stage,survival time.Results T stage (unmethylated group:T1:14,T2:2,T3:1,T4:0,partially methylated group:T1:4,T2:4,T3:3,T4:2:methylated group:T1:2,T2:10,T3:0,T4:0),AJCC renal cell carcinoma stage (unmethylated group:I stage:12,Ⅱstage:1,Ⅲ stage:0,Wstage:4; partially methylated group:Ⅰ stage:2,] stage:4,Ⅲ stage:2,Ⅳstage:5; methylated group:Ⅰ stage:1,Ⅱ stage:10,Ⅲstage:1,Ⅳstage:0),total bile acid [TBA:unmethylated group:(7.43 ±4.59) μmol/L,partially methylated group:(4.44 ± 1.75) μmol/L,methylated group:(3.97 ±3.57) μmol/L],creatine [CRE,unmethylated group:(91.7 ± 24.8) μmol/L,partially methylated group:(109.0 ±22.2) μmol/L,methylated group:(82.7 ± 19.1) μmol/L],cholesterol [CHO,unmethylated group:(4.88 ±0.95) mmoL/L,partially methylated group:(4.78 ± 1.14)mmol/L,methylated group:(3.97 ±0.69) mmol/L] and tumor diameter (unmethylated group:(5.44 ±1.96) cm,partially methylated group:(7.15 ±3.10) cm,methylated group:(8.22 ±2.60) cm were stastically significant among 3 groups with different methylation status of TMEFF2 (17 were unmethylated,13 were partially methylated and 12 were methylated).Conclusion Methylation of TMEFF2 probablly participate in the carcinogenesis and development of clear cell RCC and they deserve being futher investigated.
